Reduced weight and heart benefits for women on Ozempic
A recent study showed that women can lose
While Wegovy is the only GLP1 Receptor Agonist approved for heart health, the studies rolling in for other medications are still showing great results.
Check out our quick explainer
The study that just came out is quite specific but it's results are astounding.
The American Journal of Cardiology published a study that was focused mostly on Heart Failure with preserved Ejection Fraction ("HFpEF"):
Contributors to Wikimedia projects
This study incidentally found that women lost more weight than men when put on a regimen of Semaglutide (Ozempic) for 52 weeks.
In general, they found that both men and women benefited from taking Semaglutide – symptoms related to heart failure improved for everyone.
What was surprising was that women lost more weight than men, when on the drug for the same amount of time. There are many possible reasons:
- Fat distributions
- Not accounting for body size in dosage
- Amount of lean muscle in men vs women
But in general – since women are more likely to contract HFpEF, this was great news for both men and women.
